Inventurus Knowledge Solutions IPO Day 2 Live Updates: Key Highlights, Subscription Status, and Insights
Inventurus Knowledge Solutions (IKS) is a healthcare solutions provider offering a care enablement platform that combines technology and human expertise. It has come up with an IPO. The subscription for the same started yesterday. Today, the 13th of December 2024, is the Day 2 of the IPO applications
Inventurus Knowledge Solutions IPO Details
- Inventurus Knowledge Solutions IPO is a book built issue of Rs 2,497.92 crores. The issue is entirely an offer for sale of 1.88 crore shares.
- Inventurus Knowledge Solutions IPO bidding opened for subscription on December 12, 2024 and will close on December 16, 2024.
- The allotment for the Inventurus Knowledge Solutions IPO is expected to be finalized on Tuesday, December 17, 2024.
- Inventurus Knowledge Solutions IPO will list on BSE and NSE with a tentative listing date fixed as Thursday, December 19, 2024.
- The IPO price band is set at ₹1265 to ₹1329 per share.
- The minimum lot size for an application is 11 Shares. The minimum amount of investment required by retail investors is ₹14,619. The minimum lot size investment for sNII is 14 lots (154 shares), amounting to ₹204,666, and for bNII, it is 69 lots (759 shares), amounting to ₹1,008,711.
Inventurus Knowledge Solutions IPO Day 2 Subscription Status
(December 13, 2024, 12:13:14 PM)
Inventurus Knowledge Solutions IPO subscribed 1.74 times by December 13, 2024 12:13:14 PM.
- The Non-Institutional Investors (NIIs) subscribed to 1.49 times their allotted quota.
- The Retail Investors segment received an encouraging response, with subscriptions reaching 2.73 times their allocation.
- The QIB category subscribed to 1.55 times their allotted quota.
Utilization of IPO Proceeds
As it is a 100% Offer For Sale IPO, the company will not receive any proceeds from the Offer and all such proceeds (net of any offer-related expenses to be borne by the Selling Shareholders) will go to the Selling Shareholders.
Shareholding Pre & Post Issue
|
Shareholding |
% |
|
Shareholding Pre Issue |
69.73 |
|
Shareholding Post Issue |
60.61 |
Inventurus Knowledge Solutions Business Overview
Inventurus Knowledge Solutions (IKS) is a healthcare solutions provider offering a care enablement platform that combines technology and human expertise. It supports healthcare organizations globally in managing clinical, operational, and administrative tasks. The company caters to both inpatient and outpatient care through its proprietary technology and diverse offerings. Some of its key clients include Mass General Brigham, Texas Health Care, GI Alliance Management, and Boston Children's Health Physicians. The firm recently acquired Aquity Holdings to enhance its capabilities in clinical documentation and medical coding.
Inventurus Knowledge Solutions Limited offers a platform that enables healthcare enterprises in outpatient and inpatient care:
- Outpatient service facilities, also known as ambulatory care, provide medical care without requiring admission to a hospital or other facility and include observation, consultation, diagnosis, rehabilitation, intervention, and treatment services.
- Inpatient care refers to the provision of medical treatment for patients who have been admitted to a hospital or medical facility, requiring an overnight stay or an extended duration.
As of September 30, 2024, IKS serves over 778 healthcare organizations, including health systems, multi-specialty medical groups, and other outpatient and inpatient providers. Key clients include Mass General Brigham Inc., Texas Health Care PLLC, and The GI Alliance Management.
Inventurus Knowledge Solutions Financials
Inventurus Knowledge Solutions Limited's revenue, profit after tax (PAT), and Net Worth has shown decent growth between the financial year ending with March 31, 2024 and March 31, 2023.
- Revenues have increased from 1060.16 Cr for the period ending March 2023 to 1857.94r for the period ending March 2024, registering a healthy growth of 75.25%.
- Profits have increased from 305.23 Cr in March 2023 to 370.49 Cr in March 2024, registering a healthy growth of 21.38%.